First‐in‐human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS‐962212, a direct, reversible, small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects

AIMS: The aims of the present study were to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of BMS‐962212, a first‐in‐class factor XIa inhibitor, in Japanese and non‐Japanese healthy subjects. METHODS: This was a randomized, placebo‐controlled, double‐blind, sequential, ascending‐...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Clin Pharmacol
Autori principali: Perera, Vidya, Luettgen, Joseph M., Wang, Zhaoqing, Frost, Charles E., Yones, Cynthia, Russo, Cesare, Lee, John, Zhao, Yue, LaCreta, Frank P., Ma, Xuewen, Knabb, Robert M., Seiffert, Dietmar, DeSouza, Mary, Mugnier, Pierre, Cirincione, Brenda, Ueno, Takayo, Frost, Robert J. A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2018
Soggetti:
Clinical Trials
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5903252/
https://ncbi.nlm.nih.gov/pubmed/29346838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13520
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi